Healthcare IT News September 10, 2024
Anthony Vecchione

AlphaProteo was created to advance drug design and disease understanding by helping researchers configure high-strength proteins that bind to molecules.

Google DeepMind announced the launch of AlphaProteo, an AI system to help biological and health researchers design novel, high-strength proteins that bind to target molecules with accuracy and strength.

AlphaProteo was trained on the Protein Data Bank (PDB) that enables breakthroughs in science and education by providing access and tools for exploration, visualization and analysis of experimentally-determined 3D structures from the PDB archive.

Due to the structure of a target molecule and a set of favorite binding locations on that molecule, AlphaProteo creates a candidate protein that binds to the target.

The tech giant said binders have the potential...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: AI (Artificial Intelligence), Biotechnology, Pharma / Biotech, Technology
Cofactor AI Nabs $4M to Combat Hospital Claim Denials with AI
Set Your Team Up to Collaborate with AI Successfully
What’s So Great About Nvidia Blackwell?
Mayo develops new AI tools
Medtronic, Tempus testing AI to find potential TAVR patients

Share This Article